NCT04088422 Cell Free DNA in Mature B-cell Lymphoma
| NCT ID | NCT04088422 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ruijin Hospital |
| Condition | Mature B-Cell Lymphoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 320 participants |
| Start Date | 2022-09-28 |
| Primary Completion | 2024-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 320 participants in total. It began in 2022-09-28 with a primary completion date of 2024-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to assess whether plasma cell free DNA is an accurate tool that can early and dynamically inform on treatment outcome and an accessible source of tumor DNA to track tumor clonal evolution.
Eligibility Criteria
Inclusion Criteria: * Documented diagnosis of mature B-cell tumor according to WHO 2008 criteria * 18 years or older Exclusion Criteria: * Chemotherapy before * Other tumors
Contact & Investigator
Weili Zhao, MD，PhD
PRINCIPAL INVESTIGATOR
Ruijin Hospital
Frequently Asked Questions
Who can join the NCT04088422 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Mature B-Cell Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04088422 currently recruiting?
Yes, NCT04088422 is actively recruiting participants. Contact the research team at zhao.weili@yahoo.com for enrollment information.
Where is the NCT04088422 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT04088422 clinical trial?
NCT04088422 is sponsored by Ruijin Hospital. The principal investigator is Weili Zhao, MD，PhD at Ruijin Hospital. The trial plans to enroll 320 participants.